NewAmsterdam Pharma reported revenue of $3.70M and net income of -$64.14M for the quarter ended Jun 2026, down 80.7% year over year. This income statement covers 16 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2021 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 24.13M | 81.56M | 81.77M | 82.32M | 82.47M | 82.47M | 89.72M | 90.02M | 92.17M | 108.06M | 112.17M | 112.51M | 113.17M | 114.40M | 116.64M | 117.65M |
| Revenue & cost | ||||||||||||||||
| Revenue | 8.63M | 1.72M | 2.94M | 0.80M | 1.40M | 2.28M | 29.11M | 12.77M | 2.98M | 19.14M | 0.35M | 0.03M | 3.04M | 3.70M | ||
| Operating items | ||||||||||||||||
| Research & DevelopmentR&D | 40.42M | 34.34M | 43.37M | 41.29M | 42.43M | 38.38M | 35.70M | 34.90M | 44.75M | 27.52M | 30.97M | 38.59M | 38.01M | 41.67M | ||
| Share-based Compensation (IS) | 7.92M | 8.29M | 8.00M | 9.41M | 15.21M | 15.18M | 15.01M | 14.02M | 18.00M | 18.38M | ||||||
| Selling, General & AdministrativeSG&A | 8.06M | 9.86M | 9.13M | 10.59M | 14.45M | 16.48M | 18.41M | 21.11M | 27.15M | 27.26M | 24.52M | 27.42M | 23.45M | 26.89M | ||
| Operating ExpensesOpex | 48.48M | 44.20M | 52.50M | 51.88M | 56.88M | 54.85M | 54.11M | 56.00M | 71.90M | 54.78M | 55.49M | 66.01M | 61.46M | 68.56M | ||
| Operating IncomeOp. Inc | -39.85M | -42.48M | -49.56M | -51.07M | -55.48M | -52.58M | -25.00M | -43.23M | -68.92M | -35.63M | -55.14M | -65.98M | -58.42M | -64.86M | ||
| EBIT | -39.85M | -42.48M | -49.56M | -51.07M | -55.48M | -52.58M | -25.00M | -43.23M | -68.92M | -35.63M | -55.14M | -65.98M | -58.42M | -64.86M | ||
| Non-operating items | ||||||||||||||||
| Non Operating Investment Income | -0.00M | |||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.94M | 4.61M | 3.06M | 2.67M | 3.08M | 4.87M | 4.44M | 4.49M | 7.35M | 7.05M | 6.71M | 6.47M | 5.65M | 5.81M | ||
| Other Non Operating IncomeOther Non Op Inc. | 3.07M | -0.07M | -3.15M | 5.22M | -2.42M | -0.99M | 4.68M | -7.87M | 4.29M | 8.63M | 0.22M | -0.08M | -1.61M | -0.53M | ||
| Net income details | ||||||||||||||||
| EBT | -42.02M | -38.29M | -47.13M | -49.47M | -93.77M | -39.01M | -16.65M | -92.18M | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M | -64.14M | ||
| Tax ProvisionsTaxes | -0.00M | |||||||||||||||
| Profit After TaxPAT | -42.02M | -38.29M | -47.13M | -49.47M | -93.77M | -39.01M | -16.65M | -92.18M | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M | -64.14M | ||
| Income from Continuing OperationsIncome (Continuing) | -42.02M | -38.29M | -47.13M | -49.47M | -93.77M | -39.01M | -16.65M | -92.18M | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M | -64.14M | ||
| Consolidated Net IncomeConsol Net Inc. | -42.02M | -38.29M | -47.13M | -49.47M | -93.77M | -39.01M | -16.65M | -92.18M | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M | -64.14M | ||
| Income towards Parent CompanyParent Net Inc | -42.02M | -38.29M | -47.13M | -49.47M | -93.77M | -39.01M | -16.65M | -92.18M | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M | -64.14M | ||
| Net Income towards Common StockholdersNet Income | -42.02M | -38.29M | -47.13M | -49.47M | -93.77M | -39.01M | -16.65M | -92.18M | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M | -64.14M | ||
| Additional items | ||||||||||||||||
| EPS (Basic) | -0.51 | -0.47 | -0.57 | -0.60 | -1.06 | -0.41 | -0.18 | -0.98 | -0.34 | -0.15 | -0.61 | -0.63 | -0.40 | -0.52 | ||
| EPS (Diluted) | -0.51 | -0.47 | -0.57 | -0.60 | -1.06 | -0.41 | -0.18 | -0.98 | -0.34 | -0.15 | -0.61 | -0.63 | -0.40 | -0.52 | ||
| Shares Outstanding | 24.13M | 81.56M | 81.63M | 82.06M | 82.47M | 82.16M | 88.38M | 94.71M | 94.75M | 94.36M | 116.12M | 118.56M | 119.00M | 118.42M | 121.72M | 123.37M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 11.33M | 18.97M | 81.63M | 82.06M | 82.47M | 82.16M | 88.38M | 94.71M | 94.75M | 94.36M | 116.12M | 118.56M | 119.00M | 118.42M | 121.72M | 123.37M |
| EBITDA | -39.84M | -42.47M | -49.54M | -51.06M | -55.47M | -52.56M | -24.98M | -43.18M | -68.87M | -35.59M | -55.08M | -65.92M | -58.36M | -64.81M |
Pull NewAmsterdam Pharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=NAMS&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "NAMS", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=NAMS&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();